SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its ...
Ghent, Belgium – April 30, 2026 – Confo Therapeutics, a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a ...
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation ATLANTA, GA - April ...
Clinical Trials Arena on MSN
First patient dosed in Newleos’ Phase Ib trial of NTX-2001
The trial assesses reductions in alcohol consumption, cravings, pharmacokinetics, safety and tolerability of NTX-2001.
Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...
Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 ...
-- Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokinetics -- SBS-147 is a novel and potent oral analgesic with a differentiated safety profile being developed for acute ...
SBS-147 is a novel and potent oral analgesic with a differentiated safety profile being developed for acute and chronic pain The phase 1 SAD/MAD and phase 2 clinical study of SBS-147 are supported by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results